Ronald M Krauss1. 1. University of California, San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: Levels of small, dense low-density lipoprotein (LDL) (sdLDL) particles determined by several analytic procedures have been associated with risk of atherosclerotic cardiovascular disease (ASCVD). This review focuses on the clinical significance of sdLDL measurement. RECENT FINDINGS: Results of multiple prospective studies have supported earlier evidence that higher levels of sdLDL are significantly associated with greater ASCVD risk, in many cases independent of other lipid and ASCVD risk factors as well as levels of larger LDL particles. A number of properties of sdLDL vs. larger LDL, including reduced LDL receptor affinity and prolonged plasma residence time as well as greater oxidative susceptibility and affinity for arterial proteoglycans, are consistent with their heightened atherogenic potential. Nevertheless, determination of the extent to which sdLDL can preferentially impact ASCVD risk compared with other apoprotein B-containing lipoproteins has been confounded by their metabolic interrelationships and statistical collinearity, as well as differences in analytic procedures and definitions of sdLDL. SUMMARY: A growing body of data points to sdLDL concentration as a significant determinant of ASCVD risk. Although future studies should be aimed at determining the clinical benefit of reducing sdLDL levels, there is sufficient evidence to warrant consideration of sdLDL measurement in assessing and managing risk of cardiovascular disease. VIDEO ABSTRACT: https://www.dropbox.com/s/lioohr2ead7yx2p/zoom_0.mp4?dl=0.
PURPOSE OF REVIEW: Levels of small, dense low-density lipoprotein (LDL) (sdLDL) particles determined by several analytic procedures have been associated with risk of atherosclerotic cardiovascular disease (ASCVD). This review focuses on the clinical significance of sdLDL measurement. RECENT FINDINGS: Results of multiple prospective studies have supported earlier evidence that higher levels of sdLDL are significantly associated with greater ASCVD risk, in many cases independent of other lipid and ASCVD risk factors as well as levels of larger LDL particles. A number of properties of sdLDL vs. larger LDL, including reduced LDL receptor affinity and prolonged plasma residence time as well as greater oxidative susceptibility and affinity for arterial proteoglycans, are consistent with their heightened atherogenic potential. Nevertheless, determination of the extent to which sdLDL can preferentially impact ASCVD risk compared with other apoprotein B-containing lipoproteins has been confounded by their metabolic interrelationships and statistical collinearity, as well as differences in analytic procedures and definitions of sdLDL. SUMMARY: A growing body of data points to sdLDL concentration as a significant determinant of ASCVD risk. Although future studies should be aimed at determining the clinical benefit of reducing sdLDL levels, there is sufficient evidence to warrant consideration of sdLDL measurement in assessing and managing risk of cardiovascular disease. VIDEO ABSTRACT: https://www.dropbox.com/s/lioohr2ead7yx2p/zoom_0.mp4?dl=0.
Authors: Allan D Sniderman; George Thanassoulis; Tamara Glavinovic; Ann Marie Navar; Michael Pencina; Alberico Catapano; Brian A Ference Journal: JAMA Cardiol Date: 2019-12-01 Impact factor: 14.676
Authors: Samia Mora; Michael P Caulfield; Jay Wohlgemuth; Zhihong Chen; H Robert Superko; Charles M Rowland; Robert J Glynn; Paul M Ridker; Ronald M Krauss Journal: Circulation Date: 2015-09-25 Impact factor: 29.690
Authors: P J Barter; C M Ballantyne; R Carmena; M Castro Cabezas; M John Chapman; P Couture; J de Graaf; P N Durrington; O Faergeman; J Frohlich; C D Furberg; C Gagne; S M Haffner; S E Humphries; I Jungner; R M Krauss; P Kwiterovich; S Marcovina; C J Packard; T A Pearson; K Srinath Reddy; R Rosenson; N Sarrafzadegan; A D Sniderman; A F Stalenhoef; E Stein; P J Talmud; A M Tonkin; G Walldius; K M S Williams Journal: J Intern Med Date: 2006-03 Impact factor: 8.989
Authors: Jan Borén; M John Chapman; Ronald M Krauss; Chris J Packard; Jacob F Bentzon; Christoph J Binder; Mat J Daemen; Linda L Demer; Robert A Hegele; Stephen J Nicholls; Børge G Nordestgaard; Gerald F Watts; Eric Bruckert; Sergio Fazio; Brian A Ference; Ian Graham; Jay D Horton; Ulf Landmesser; Ulrich Laufs; Luis Masana; Gerard Pasterkamp; Frederick J Raal; Kausik K Ray; Heribert Schunkert; Marja-Riitta Taskinen; Bart van de Sluis; Olov Wiklund; Lale Tokgozoglu; Alberico L Catapano; Henry N Ginsberg Journal: Eur Heart J Date: 2020-06-21 Impact factor: 29.983